Full-Time
Technical Application Scientist
Parse Biosciences
51-200 employees
Provides single-cell analysis kits and software
No salary listed
Remote in UK
Remote
Remote in the United Kingdom or Europe; occasional travel to Seattle HQ for conferences/trainings.
Bachelor's
 Lab & Research (1) |
|---|
Get referred to Parse Biosciences
See people who can refer or advise you
- Minimum of a BA/BS in Chemistry, Biochemistry, Molecular Biology or Genetics
- Minimum of one (1) year of experience in a customer-facing role supporting genomics products
- Experience with next-generation sequencing platforms and library preparation, cell culture, RNA-Seq
- A proactive and collaborative approach to problem solving
- Outstanding communication skills, written and verbal, as well as excellent interpersonal skills
- Someone who works well in a fast-paced, dynamic environment
- Proficiency with MS Office and Google Suite (Mail, Calendar), CRM (e.g. Hubspot, Salesforce), and ideally Monday.com (or similar for project management)
- Knowledge of gene expression data analysis, analysis tools, basic command line knowledge is highly desired
Parse Biosciences provides tools and software for single-cell analysis to genomics and molecular biology researchers. Their core offering centers on splitting cells into nuclei suspensions, labeling each cell with a unique barcode through split-pool combinatorial barcoding, and then sequencing and analyzing data. The end-to-end solution includes sample prep, sequencing, and data interpretation through their Trailmaker software, designed to work without expensive custom instruments. The company differentiates itself by delivering a scalable, kit-based workflow plus integrated software that allows researchers to perform high-throughput single-cell analysis in-house, reducing reliance on specialized equipment and outsourcing. The goal is to democratize access to advanced single-cell techniques, enabling more scientists and institutions to study biological systems and diseases at the single-cell level.
Company Size
51-200
Company Stage
Acquired
Total Funding
$99.7M
Headquarters
Seattle, Washington
Founded
2018
Get referred to Parse Biosciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 2026 bit.bio alliance targets predictive-medicine datasets and human cell manufacturing.
- July 2026 Xpress Genomics became Parse's first Nordic Certified Service Provider.
- 2026 FFPE launch opens archived tissue markets across oncology and neuroscience.
What critics are saying
- QIAGEN's 2025 acquisition puts Parse's roadmap under corporate integration and repricing.
- Illumina and 10x Genomics can undercut Parse with entrenched instrument ecosystems by 2027.
- If GigaLab utilization stalls, Parse becomes a commoditized reagent brand inside QIAGEN.
What makes Parse Biosciences unique
- QIAGEN-owned Parse ships instrument-free Evercode, avoiding costly microfluidics.
- March 2026 Evercode v4 scales to five million cells and 384 samples.
- FFPE kits, Trailmaker, and GigaLab bundle prep, analysis, and industrial-scale services.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
Company Equity
Paid Holidays
Paid Vacation
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -3%News & articles. At ConnectWeb Connectweb has a team of editors and researchers collating the most relevant information to you and your industry. All Directories' publications and sites provide a wealth of information for research or marketing, and are used by public and corporate libraries, educational institutions, government departments, corporations and SMEs across the country. You are here: Home News Access the latest company news and announcements distributed through Medianet. Medical, Health & Aged Care 29/07/2026 22:17 Xpress Genomics joins Parse Biosciences' Certified Service Provider network. Parse Biosciences Stockholm-based service provider adds Evercode to its single cell sequencing offerings SEATTLE-BUSINESS WIRE- Parse Biosciences, the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics has joined its Certified Service Provider (CSP) program, becoming the first in the Nordic region. The Stockholm-based company will offer Parse's Evercode single cell sequencing portfolio to researchers through its existing sequencing service pipeline. Originating out of the Karolinska Institutet in 2022, Xpress Genomics has built automated, in-house workflows for NGS projects. Joining the CSP program adds Evercode to the company's service offerings, giving its customers direct access to Parse's split-pool single cell technology. "Our customers expect fast, high-quality results," said Christoph Ziegenhain, CEO at Xpress Genomics. "Offering Evercode through our CSP membership gives them a strong option for single cell projects, backed by the same turnaround and quality standards our lab runs on." "Adding Xpress Genomics to our CSP program means researchers get access to a lab known for speed and precision," said Charlie Roco, PhD, Co-Founder and Chief Technology Officer at Parse Biosciences. "Their track record with high-throughput sequencing pairs well with Evercode's scalability, giving researchers another strong option for their single cell projects." About Xpress Genomics Xpress Genomics is a Stockholm-based NGS service provider founded by researchers at Karolinska Institutet. Leveraging deep expertise in RNA biology, the company has developed automated, in-house workflows that allow them to fulfill their mission: providing accessible, high-quality sequencing services that accelerate the pace of scientific discovery. About Parse Biosciences Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Contact details: * images - purple_logo.jpg download. ConnectWeb. ConnectWeb is Australia's leading publisher of biographical data, directories and specialist newsletters. With ConnectWeb you gain access to its comprehensive database of contacts and companies in media, government and associations. Connect with Connectweb.
Parse Biosciences and bit.bio announce landmark alliance. Business Wire Published May 27, 2026 Article content Unlocking Cell Fate: Alliance will power AI-driven predictive medicine and human cell manufacturing Article content SEATTLE - Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at scale. By precisely mimicking in vivo biological responses, these models will significantly advance predictive drug discovery and therapeutic development. Article content Advertisement 1 Story continues below This advertisement has not loaded yet, but your article continues below. Article content This collaboration doesn't just generate data; it provides a foundational map for bit.bio to scale human-relevant models and feed predictive AI systems, moving the entire field closer to reliably replicating and predicting human biology. Article content The alliance will leverage cutting-edge techniques in massively parallel causal transcriptomics, which allows scientists to test thousands of genetic variables simultaneously to understand what drives cell behavior. bit.bio will contribute its industry-leading cell programming technology, opti-ox(TM), as well as its proprietary Discovery platform, The Cell Foundry(TM), and Parse its scalable single cell technology, Evercode(TM). The result will build on existing proprietary data to an unprecedented bit.bio dataset that maps how specific genetic inputs lead to specific biological outputs. Ultimately, this dataset will guide not only bit.bio but the wider industry on how therapies are designed and human cells manufactured at scale, while also feeding AI models that can predict how cells respond to drugs or disease. Article content Top Stories Interested in more newsletters? Browse here. Article content "Cells operate on code, and by mapping how specific transcription factors dictate cell fate, we are unlocking that operating system. This collaboration doesn't just generate data; it provides a foundational map for bit.bio to scale human-relevant models and feed predictive AI systems, moving the entire field closer to reliably replicating and therefore predicting human biology," remarks Przemek Obloj, CEO of bit.bio. Article content "Researchers need insights that they can translate into impact," states Charlie Roco, PhD, Co-founder and Chief Technology Officer at Parse Biosciences. "Our close alliance with bit.bio will create foundational datasets that establish clear causal links between genetic changes and biological outcomes, the kind of information that predictive medicine needs but has rarely had." Article content To learn more about how these data will shape the future of predictive biology modeling and manufacturing, attend the Parse webinar on June 17 at 7:00 AM Pacific Time. Article content About bit.bio Article content bit.bio, the global leader in cell programming technology, is creating functional, human-relevant cells and models at industrial scale to accelerate research, drug discovery and development, while facilitating the adoption of New Approach Methodologies (NAMs). Product development is fuelled by its AI-enabled discovery platform that identifies unique transcription factor combinations to program desired cell types, and its patented opti-ox(TM) technology that precisely converts induced pluripotent stem cells (iPSCs) into these cell types assuring unprecedented purity, consistency, and scalability. bit.bio's expanding ioCells portfolio comprises more than 50 products, including ioWild Type Cells, ioDisease Model Cells, ioCRISPR-Ready Cells, and ioTracker Cells. Article content Advertisement 2 Story continues below Article content Since spinning out from the University of Cambridge in 2016, bit.bio has raised over $200m from leading investors including Arch Venture, BlueYard Capital, Charles River Laboratories, Foresite Capital, M&G, Milky Way, National Resilience, and Tencent. Article content About Parse Biosciences Article content Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Article content View source version on businesswire.com: Article content Advertisement 1
Parse Biosciences, a QIAGEN company, has launched Evercode Whole Transcriptome FFPE kits, enabling whole transcriptome single-cell RNA sequencing from formalin-fixed, paraffin-embedded samples for the first time. The technology addresses a major limitation in accessing FFPE samples, which represent the world's largest repository of clinically annotated tissue. Previously, RNA degradation in FFPE samples forced researchers to rely on predefined gene panels, limiting full transcriptome analysis. Parse's solution uses a novel split-pool combinatorial barcoding approach and proprietary reverse transcription-based RNA capture chemistry designed for compromised RNA. The technology allows cancer, neuroscience and translational researchers to access single-cell resolution across the full transcriptome for new and archived FFPE samples. The kits are now shipping to customers.
Maximize every sample: how Evercode v4 redefines performance in Whole Transcriptome profiling. Published: 24 Mar 2026 Parse Biosciences, a part of QIAGEN known as the leading provider of scalable and accessible single-cell sequencing solutions, has launched the new Evercode(TM) Whole Transcriptome v4 product line today. This new product improves scalability, boosts sensitivity, and streamlines the workflow for single-cell RNA sequencing. Precision at scale: Parse Biosciences unveils v4 chemistry with unmatched gene sensitivity. The Evercode v4 system features impressive scalability, supporting up to five million cells and 384 samples in one run. This allows researchers to perform large studies while maintaining sample resolution. The enhanced chemistry improves gene detection per cell and reduces the number of sequencing reads needed, which helps lower overall sequencing costs. According to Precedence Research, the Specimen Retrieval Market size accounted for USD 316.22 billion in 2025 and is predicted to increase from USD 330.86 billion in 2026 to approximately USD 497.22 billion by 2035, expanding at a CAGR of 4.63% from 2026 to 2035 as demand grows for adoption of minimally invasive surgery, focus on patient safety and infection control and growing prevalence of chronic diseases. A new magnetic bead-based workflow has been introduced, replacing the traditional centrifugation steps and improving cell recovery by up to 75%. This innovation allows researchers to gather more data from limited or precious samples. The optimized process reduces hands-on time and the number of pipetting steps, and is designed to support laboratory automation, making it suitable for labs with different levels of experience in single-cell techniques. Capture every detail: enhanced Retrieval for rare cell discovery in Evercode v4. Additionally, Evercode v4 effectively removes off-target reads, which improves gene detection per cell, even at lower sequencing depths and costs compared to other options. With its high sensitivity, Evercode v4 offers better biological resolution for researchers studying rare cell types or genes with low expression levels. The chemistry behind Evercode Whole Transcriptome v4 is present across the entire Evercode Whole Transcriptome product range, which features Evercode Fixation and experiments carried out in Parse's GigaLab. "From the beginning, our goal has been to provide the research community with single-cell technology that is scalable, accessible, and high-performing," said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. "Evercode v4 reflects years of development and direct feedback from its users, marking a major improvement in cell recovery and sensitivity, along with a simpler workflow. A recent report by Precedence Research highlights that the Specimen Retrieval Market is benefiting from technological advancements in robotic-assisted devices, growing demand for patient safety and infection control, and increasing healthcare infrastructure investments in emerging markets.
Parse Biosciences, a QIAGEN company, has launched Evercode Whole Transcriptome v4, an upgraded single-cell RNA sequencing platform offering enhanced scalability and performance. The new chemistry supports up to five million cells and 384 samples in a single run whilst increasing gene detection per cell with fewer sequencing reads. A new magnetic bead-based workflow replaces centrifugation steps, boosting cell recovery by up to 75% and reducing hands-on time. The system eliminates off-target reads, enabling higher gene detection at lower sequencing depths and costs. The streamlined process is designed to support laboratory automation, making it accessible to labs with varying experience levels. Evercode v4 is available across the entire Evercode Whole Transcriptome product line and is planned to begin shipping in March 2026.